The current PE ratio of MRNA can't be determined, as the TTM EPS of -$12.33 is negative. The last recorded PE ratio for Moderna was 39.19 in June 2023.
The average historical PE ratio of Moderna for the last four years is 22.07. Over the past four years, MRNA's PE ratio was at its highest in the Mar 2021 quarter at 90.31, when the stock price was $130.95 and the EPS was $1.45. The lowest value was in the Sep 2022 quarter, when it reached 4.03 with a price of $118.25 and an EPS of $29.37.
Maximum annual increase: 0.84% in 2022
| Year | PE ratio | Change |
|---|---|---|
| 2023 | N/A | N/A |
| 2022 | 8.45 | 0.84% |
| 2021 | 8.38 | N/A |
| 2020 | N/A | N/A |
| 2019 | N/A | N/A |
| 2018 | N/A | N/A |
| 2017 | N/A | N/A |
| 2016 | N/A | N/A |
| Stock name | PE ratio | Market cap |
|---|---|---|
| JNJ Johnson & Johnson | 10.7 | $357.77B |
| NVS Novartis AG | 13.27 | $200.67B |
| MRK Merck & Co Inc | 907.14 | $321.65B |
| RGLS Regulus Therapeutics Inc | N/A | $145.33M |
| ARWR Arrowhead Pharmaceuticals Inc | N/A | $2.89B |
| ALNY Alnylam Pharmaceuticals Inc | N/A | $18.11B |
| MRNA Moderna Inc | N/A | $41.59B |
The current price to earnings ratio of MRNA can't be calculated, as its EPS of -$12.33 is negative.
The 3-year average PE ratio for MRNA stock is 14.48.
The 5-year average PE ratio for MRNA stock is 22.07.
In the last four years, the Mar 2021 quarter recorded the highest quarterly PE ratio at 90.31.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.